STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion




STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion

Higher reimbursement, regulatory clarity, and acknowledgment of future indication expansion expected to reinforce physician confidence and support continued expansion

HORSHAM, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in excimer laser therapy for inflammatory and autoimmune dermatologic diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its CY 2026 Medicare Physician Fee Schedule Final Rule confirming continued reimbursement for excimer laser treatments under CPT^® codes 96920, 96921, and 96922, while recognizing the upcoming expansion of CPT code descriptors to include inflammatory and autoimmune skin conditions beyond psoriasis—effective January 1, 2027.

In the Final Rule, CMS recognized the excimer laser as a well-established treatment modality, affirmed continued coverage as well as increase in payment for calendar year (CY) 2026, and indicated it will review extensive clinical and real-world cost data submitted by STRATA and other stakeholders as part of CY 2027 rulemaking alongside the American Medical Association (AMA) CPT Editorial Panel revisions and the RUC’s recommendations. The final rule confirms that at-least until the CPT code language changes take effect on January 1, 2027, the current code family remains exclusive to excimer laser technology.

Strata directly and through advocacy groups is actively engaging commercial insurance providers to educate them on the upcoming changes and make sure the individual coverage policies will extend the excimer laser exclusivity as the only clinically proven technology far beyond 2027.

“We appreciate CMS’ recognition of upcoming indication expansion and the robust clinical and cost input data submitted by STRATA and the clinical community,” said Dr. Dolev Rafaeli, STRATA’s President and CEO. “This acknowledgment—and the CMS plan to incorporate these inputs in the 2027 rulemaking—marks an important step forward. This reinforces confidence in excimer laser procedure reimbursement, supports our network of over 840 partner clinics and the several hundred owners of XTRAC^® and Pharos^® (the only excimer laser devices available in the domestic market, both owned by STRATA) which are the immediate available source of expansion for the STRATA go-to-market strategy. The CMS decisions further strengthen our long-term strategy to expand adoption of the use of excimer laser procedures across immune-mediated skin diseases. We believe this ruling provides regulatory clarity and long-term tailwinds as we expand excimer utilization and accelerate physician adoption moving into 2026 and beyond. In the meantime, we remain focused on protecting patient access and supporting providers as we work toward expanded code descriptors, while maintaining ethical billing of these reimbursement codes.”

Key Takeaways

• Continued Medicare Coverage: CMS confirms ongoing reimbursement for excimer laser treatments under CPT 96920–96922, ensuring uninterrupted patient access
• Increased Reimbursement: The Final Rule increases 2026 payment for all three codes by approximately 3.5% versus 2025
• Excimer Laser Exclusivity: CPT 96920–96922 remain in effect and apply exclusively to excimer laser technology when applying for insurance reimbursement until at least the 2027 descriptor updates. This decision further supports STRATA’s position that no other technology, including solid-state lasers should be sold as reimbursable or ethically be billed for insurance reimbursement under these codes
• Recognition of Expanded Indications (2027): CMS acknowledges the AMA CPT Editorial Panel’s milestone May 2025 revisions broadening excimer laser procedure eligibility for reimbursement under the codes to additional inflammatory and autoimmune conditions (e.g., vitiligo, atopic dermatitis, alopecia areata), effective January 1, 2027
• Real-World Inputs Considered: CMS will evaluate stakeholder data on clinical outcomes, utilization, and practice expense as part of the CY 2027 process

Commitment to Patients and Providers

STRATA’s FDA-cleared and clinically proven XTRAC^® excimer laser delivers targeted 308-nm UVB therapy used by dermatologists to treat psoriasis, vitiligo, atopic dermatitis, and other inflammatory and autoimmune skin diseases. The Company will continue partnering with clinicians, patient advocates, and payers to ensure safe, effective, non-systemic treatment options remain available and appropriately recognized.

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC^® excimer laser, VTRAC^® lamp systems, and the TheraClear^®X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Safe Harbor

This press release includes “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, tariffs, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.

Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy




Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

– Innovation Passport award facilitates accelerated time to market and helps expedite patient access to transformative new medicines – 

– New Innovative Licensing and Access Pathway (ILAP) designation provides unique, end-to-end regulatory access pathway for Solid to work directly with the UK’s National Health System (NHS), the UK Medicines and Healthcare products Regulatory Agency (MHRA) and health technology assessment (HTA) bodies: the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the All Wales Therapeutics and Toxicology Centre (AWTTC) –

– Innovation Passport supports the potential for SGT-003 to become the first-to-market gene therapy in the UK for Duchenne muscular dystrophy –

CHARLESTOWN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that SGT-003, the Company’s investigational gene therapy for Duchenne muscular dystrophy (Duchenne), has been granted an Innovation Passport under the new ILAP. The Innovation Passport is the entry point for the ILAP, which aims to accelerate time to market and facilitate patient access to new medicines in the UK. The Innovation Passport activates the MHRA and the ILAP partner agencies to develop a product-specific roadmap for regulatory and development milestones.

SGT-003 is one of the first three investigational medicinal products joining the new ILAP, which focuses more selectively on transformative products that address unmet clinical needs.

Jessie Hanrahan, Ph.D., Chief Regulatory & Preclinical Operations Officer of Solid Biosciences, said, “Receiving the Innovation Passport designation is further recognition of SGT-003’s potential to transform the treatment paradigm for those living with Duchenne. We are thrilled to have received this designation, which provides early and enhanced interactions with regulators and access to development tools designed to enable accelerated regulatory timelines. We are committed to delivering on SGT-003’s promise globally and we look forward to collaborating closely with the UK MHRA and other ILAP partners to bring this potential new therapy to patients as quickly as possible.”

Emily Reuben, Co-founder and CEO of Duchenne UK, said, “Having been a member of the Patient Reference Group that helped to shape the original Innovation Passport Designation, it’s fantastic to see an investigational medicinal product for Duchenne now benefiting from it. Duchenne UK works closely with regulators, industry and partners globally to try to break down barriers at every stage of the drug development process and to accelerate access to potentially transformative treatments for people living with Duchenne. We hope the new ILAP will deliver on its aim of streamlining and speeding up the development and access for SGT-003, and ultimately, if the data support it, deliver access to a promising new treatment for patients in the National Health Service (NHS). We look forward to working with Solid Biosciences and regulators here in the UK as SGT-003 is developed further.”

SGT-003 is currently being evaluated in the ongoing Phase 1/2 INSPIRE DUCHENNE clinical trial, which is enrolling participants at 15 active clinical trial sites across the US, UK, Italy and Canada. Additionally, Solid has activated the first clinical trial site and is screening participants for IMPACT DUCHENNE, an ex-US, Phase 3, randomized, double-blind, placebo-controlled clinical trial of SGT-003.

About ILAP
The ILAP was first launched in 2021 to accelerate development of and access to promising medicines. The relaunched ILAP is the only end-to-end access pathway in the world where early multi-stakeholder engagement is established at an early stage of clinical development. The new pathway features enhanced input and interactions with the MHRA and the ILAP partners, including the All Wales Therapeutics and Toxicology Centre (AWTTC), the National Institute for Health and Care Excellence (NICE) the Scottish Medicines Consortium (SMC) and the NHS. Other benefits of the ILAP include access to a range of services that support clinical development (including clinical trial delivery), market access, and health system adoption, reducing the end-to-end timeline for product R&D and facilitating rapid access to the UK market. More information about the ILAP can be found here.

About Duchenne
Duchenne is a genetic muscle-wasting disease predominantly affecting boys, with symptoms usually appearing between three and five years of age. Duchenne is a progressive, irreversible, and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births and has an estimated prevalence of 5,000 to 15,000 cases in the United States alone.

About SGT-003
SGT-003 is an investigational gene therapy containing a differentiated microdystrophin construct and a proprietary, next-generation capsid, AAV-SLB101, which was rationally designed to target integrin receptors, and has shown enhanced cardiac and skeletal muscle transduction with decreased liver targeting in nonclinical studies. SGT-003’s microdystrophin construct uniquely includes the R16/17 domain, which localizes nNOS to the muscle. Nonclinical studies have shown that nNOS can improve blood flow to the muscle thereby reducing muscle breakdown from ischemia and muscle fatigue. Together, these design features suggest that SGT-003 could be a potential best-in-class investigational gene therapy for the treatment of Duchenne.

About INSPIRE DUCHENNE
INSPIRE DUCHENNE is a first-in-human, open-label, single-dose, multicenter Phase 1/2 clinical trial to evaluate the safety, tolerability and efficacy of SGT-003 in pediatric participants with a genetically confirmed Duchenne diagnosis with a documented dystrophin gene mutation. INSPIRE DUCHENNE is a multinational trial designed to enroll participants in the United States, Canada, the United Kingdom and Italy.

About IMPACT DUCHENNE
IMPACT DUCHENNE is a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy of a single dose of SGT-003 in pediatric participants with a genetically confirmed Duchenne diagnosis with a documented dystrophin gene mutation. IMPACT DUCHENNE is a multinational trial designed to enroll participants outside of the United States with the aim of supporting potential ex-U.S. regulatory authorizations.

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the company; the ability to successfully achieve and execute on the company’s goals, priorities and key clinical and preclinical milestones; strategies and expectations for the company’s SGT-003 and other programs, ; expectations for additional site activations, planned enrollment, planned regulatory interactions and the potential approval pathways for SGT-003; timing of planned clinical trials of SGT-003; t the sufficiency of the Company’s cash, cash equivalents, and available-for-sale securities to fund its operations; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “working” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the company’s ability to advance SGT-003 and other programs, capsid libraries and other enabling technologies on the timelines expected or at all; obtain and maintain necessary approvals from the FDA and other regulatory authorities; replicate in clinical trials positive results found in preclinical studies and early-stage clinical trials of the company’s product candidates; obtain, maintain or protect intellectual property rights related to its product candidates; replicate preliminary or interim data from early-stage clinicals trials in the final data of such trials; compete successfully with other companies that are seeking to develop Duchenne, FA, CPVT and other neuromuscular and cardiac treatments and gene therapies; manage expenses; and raise the substantial additional capital needed, on the timeline necessary, to continue development of SGT-003 and other candidates, achieve its other business objectives and continue as a going concern. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof and should not be relied upon as representing the company’s views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company’s views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

arcoris bio raises CHF 6.3 million seed round to advance next-generation biomarker technology for digital pathology




arcoris bio raises CHF 6.3 million seed round to advance next-generation biomarker technology for digital pathology

Schlieren, Switzerland, Nov. 06, 2025 (GLOBE NEWSWIRE) —

• Round co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) and new as well as existing private investors.
• MUSE^®, arcoris bio’s nanotechnology platform for biomarker detection and signal amplification, enables simultaneous detection of multiple biomarkers with unprecedented ease and sensitivity.
• The funding will accelerate industrialization of the MUSE^® platform, expansion of strategic partnerships, and launch of new products.

Schlieren, Switzerland, 6. November 2025 – arcoris bio, a Swiss life science research tools and in vitro diagnostics company, has secured CHF 6.3 million in an oversubscribed seed financing round to advance the development and commercialization of its breakthrough MUSE^® biomarker detection platform. The round was co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) and both existing and new private investors.

“Attracting two lead investors with deep industry expertise is a strong validation of our technical and business strategy. This support empowers us in our mission of transforming biomarker detection and digital pathology,” commented Simon Restrepo, Co-founder and CSO arcoris bio.

The financing will enable arcoris bio to industrialize MUSE^® and expand strategic partnerships and launch new products.

Matyas Vegh, CEO arcoris bio, added: “Securing this financing marks a major milestone for arcoris bio. In a challenging market, we are grateful for the trust our investors have placed in our vision. Their support empowers us to bring our innovations to market faster, strengthen our operations, and scale to meet growing industry demand.”

MUSE^® enables researchers to detect multiple biomarkers simultaneously with unprecedented ease and sensitivity. By allowing the measurement of several difficult-to-detect biomarkers within a single sample at higher throughput, MUSE® is poised to play a pivotal role in the evolution of digital pathology.

Andreas Jenne, Investment Director at Ventura Ace, said: “We have been impressed by the arcoris bio team’s vision and early traction with industry partners. We believe MUSE^® represents a truly enabling technology for digital pathology.”

“arcoris bio’s MUSE^® technology fills a critical gap in the market to enable better diagnostics and applications like drug discovery or precision medicine. Its universal applicability is particularly exciting – MUSE^® acts like a molecular GPU, amplifying the capabilities of existing biomarker platforms and opening new paths for innovation,” highlighted Benedikt Klaes, Senior Investment Manager at ZEISS Ventures.

For further information, please contact:

Beatrix Benz
+41 79 256 77 73

media@arcorisbio.com

About arcoris bio

arcoris bio develops next-generation technologies for biomarker detection in research and diagnostics. Its flagship MUSE^® platform provides universal, programmable signal amplification to enable highly sensitive and multiplex assays that drive the future of digital pathology.

The company was founded by MUSE^® inventors Simon Restrepo and Scott E. Fraser, together with entrepreneur H. Kaspar Binz, and is headquartered in Schlieren, Switzerland.
For more information, please visit: www.arcorisbio.com

Attachment

• arcoris bio_PR_Financing_Final_251106

arcoris bio raises CHF 6.3 million seed round to advance next-generation biomarker technology for digital pathology




arcoris bio raises CHF 6.3 million seed round to advance next-generation biomarker technology for digital pathology

Schlieren, Switzerland, Nov. 06, 2025 (GLOBE NEWSWIRE) —

• Round co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) and new as well as existing private investors.
• MUSE^®, arcoris bio’s nanotechnology platform for biomarker detection and signal amplification, enables simultaneous detection of multiple biomarkers with unprecedented ease and sensitivity.
• The funding will accelerate industrialization of the MUSE^® platform, expansion of strategic partnerships, and launch of new products.

Schlieren, Switzerland, 6. November 2025 – arcoris bio, a Swiss life science research tools and in vitro diagnostics company, has secured CHF 6.3 million in an oversubscribed seed financing round to advance the development and commercialization of its breakthrough MUSE^® biomarker detection platform. The round was co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) and both existing and new private investors.

“Attracting two lead investors with deep industry expertise is a strong validation of our technical and business strategy. This support empowers us in our mission of transforming biomarker detection and digital pathology,” commented Simon Restrepo, Co-founder and CSO arcoris bio.

The financing will enable arcoris bio to industrialize MUSE^® and expand strategic partnerships and launch new products.

Matyas Vegh, CEO arcoris bio, added: “Securing this financing marks a major milestone for arcoris bio. In a challenging market, we are grateful for the trust our investors have placed in our vision. Their support empowers us to bring our innovations to market faster, strengthen our operations, and scale to meet growing industry demand.”

MUSE^® enables researchers to detect multiple biomarkers simultaneously with unprecedented ease and sensitivity. By allowing the measurement of several difficult-to-detect biomarkers within a single sample at higher throughput, MUSE® is poised to play a pivotal role in the evolution of digital pathology.

Andreas Jenne, Investment Director at Ventura Ace, said: “We have been impressed by the arcoris bio team’s vision and early traction with industry partners. We believe MUSE^® represents a truly enabling technology for digital pathology.”

“arcoris bio’s MUSE^® technology fills a critical gap in the market to enable better diagnostics and applications like drug discovery or precision medicine. Its universal applicability is particularly exciting – MUSE^® acts like a molecular GPU, amplifying the capabilities of existing biomarker platforms and opening new paths for innovation,” highlighted Benedikt Klaes, Senior Investment Manager at ZEISS Ventures.

For further information, please contact:

Beatrix Benz
+41 79 256 77 73

media@arcorisbio.com

About arcoris bio

arcoris bio develops next-generation technologies for biomarker detection in research and diagnostics. Its flagship MUSE^® platform provides universal, programmable signal amplification to enable highly sensitive and multiplex assays that drive the future of digital pathology.

The company was founded by MUSE^® inventors Simon Restrepo and Scott E. Fraser, together with entrepreneur H. Kaspar Binz, and is headquartered in Schlieren, Switzerland.
For more information, please visit: www.arcorisbio.com

Attachment

• arcoris bio_PR_Financing_Final_251106

CARBIOS and Wankai New Materials, a subsidiary of Zhink Group, are committed to the large-scale deployment of CARBIOS’ PET biorecycling technology in Asia, with the first step being the construction of a PET biorecycling plant in China.




CARBIOS and Wankai New Materials, a subsidiary of Zhink Group, are committed to the large-scale deployment of CARBIOS’ PET biorecycling technology in Asia, with the first step being the construction of a PET biorecycling plant in China.

• The two Groups have reached a binding agreement on the main principles of their collaboration, with a view to deploying a capacity of one million tonnes in the long term,
• Starting with the construction of a plant in China with a processing capacity of 50,000 tonnes of PET waste per year.
• This collaboration remains subject to the signing of final agreements.

Clermont-Ferrand (France), November 6, 2025 (08:30am CET). Following the Letter of intent signed on June 24, 2024, CARBIOS (Euronext Growth Paris: ALCRB) and Wankai New Materials (“Wankai”), a listed¹ subsidiary of Zhink Group, 3^rd largest PET producer in China and 4^th globally, announce the signing of an agreement on the fundamental principles of a collaboration aiming to deploy CARBIOS PET enzymatic recycling technology in Asia.

Under the terms of this agreement, CARBIOS and Wankai would enter into a long-term commitment with the ambition to build and operate several PET biorecycling plants in Asia with a target capacity of one million tonnes per year. CARBIOS would grant, to the joint ventures formed under this agreement, an exclusive licence of CARBIOS technology for the Asian region.

The first step of this collaboration will be the creation of a joint venture dedicated to the construction and operation of a first PET biorecycling plant in China, with an annual processing capacity of 50,000 tonnes of PET waste per year. CARBIOS will grant to this entity a licence to produce PTA and MEG monomers.

The financing of this future joint venture, in which Wankai would be the main shareholder, will be guaranteed by the latter. The construction project for the first plant is expected to start in the first quarter of 2026.

In addition, Wankai would make a € 5 million investment in CARBIOS S.A.². This investment would strengthen the strategic partnership between the two companies.

This project of partnership, including the project of a first plant and investment in CARBIOS, remains subject to the finalization and signature of the definitive agreements, in particular the shareholders’ agreement and the licence agreement. The parties’ objective is to have them signed by the end of 2025.

This agreement would mark the first licence for CARBIOS’ technology whereby confirming the viability of its business model.

As the world leading producer of PET, China is a key market for CARBIOS. This agreement represents a strategic step forward for both partners, who are determined to accelerate the development of a circular PET industry in Asia.

Vincent Kamel, CEO of CARBIOS: “This agreement represents a key step in the international roll-out of our technology and an important milestone in the implementation of our licensing model. This cooperation with Wankai, China’s third-largest PET producer, will enable us to produce enzymatically recycled PET and thus make a concrete contribution to the transition to a more circular and low-carbon PET industry.”

###

About CARBIOS:
CARBIOS is a biotechnology company that develops and industrializes biological solutions to reinvent the lifecycle of plastics and textiles. Inspired by nature, CARBIOS designs enzyme-based biological processes to break down plastics, with the mission of preventing plastic and textile pollution and accelerating the transition to a circular economy. Its two innovative technologies—dedicated to PET biorecycling and PLA biodegradation—are currently scaling up to industrial and commercial levels. Its industrial demonstration plant for biorecycling has been operational since 2021, and construction of the world’s first biorecycling plant is expected to resume before the end of 2025, subject to securing the necessary additional funding. CARBIOS is supported by prestigious brands in the cosmetics, food, and apparel industries, aiming to improve the recyclability and circularity of their products. Nestlé Waters, PepsiCo, and Suntory Beverage & Food Europe are members of a packaging consortium founded by CARBIOS and L’Oréal. On, Patagonia, PUMA, PVH Corp., and Salomon collaborate with CARBIOS in a textile consortium. CARBIOS is part of the global community of B Corp™ certified companies that are transforming their business models to serve the common good.

Visit www.carbios.com to learn more about biotechnology for circular plastics and textiles.

LinkedIn : carbios / Instagram : carbios

Information on CARBIOS shares:

ISIN Code: FR0011648716
Ticker Code: Euronext Growth: ALCRB
LEI: 969500M2RCIWO4NO5F08

CARBIOS is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.

Disclaimer on forward-looking statements and risk factors:
This press release contains forward-looking statements, not historical data, and should not be construed as a guarantee that the facts and data stated will occur. These forward-looking statements are based on data, assumptions and estimates considered reasonable by CARBIOS. CARBIOS operates in a competitive and rapidly evolving environment. It is therefore not in a position to anticipate all risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of a risk or combination of risks could lead to results that differ significantly from those mentioned in any forward-looking statement. CARBIOS draws your attention to the fact that forward-looking statements are in no way a guarantee of its future performance and that its actual financial position, results, cash flows, its partnerships and corporate agreements, and the development of the sector in which CARBIOS operates may differ significantly from those proposed or suggested by the forward-looking statements contained in this document. In addition, even if CARBIOS’ financial position, results, cash flows, its partnerships and corporate agreements, and developments in the industry in which it operates are consistent with the forward-looking information contained in this document, such results or developments may not be a reliable indication of CARBIOS’ future results or developments. Readers are also advised to carefully consider the risk factors described in the Universal registration document filed with the French Market Authority (“AMF”), as well as in the half-year financial report available free of charge on the Company’s website. Should all or any part of these risk factors occur or others, in no case whatsoever will CARBIOS be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages. This information is given only as of the date of this press release. CARBIOS makes no commitment to publish updates to this information or on the assumptions on which it is based, except in accordance with any legal or regulatory obligation applicable to it.

For additional information, please contact:

1 Wankai New Materials is a company listed on the Shenzhen Stock Exchange (stock code:301216)

² As a result of this investment, Wankai could appoint a representative to CARBIOS’ Board of Directors. The terms and conditions of the capital investment, particularly the financial terms, are still to be finalized in the definitive agreements. This investment will, if necessary, be subject to administrative and regulatory approvals in France and Chine.

Attachment

• 2025 11 06 PR CARBIOS x WANKAI

CARBIOS and Wankai New Materials, a subsidiary of Zhink Group, are committed to the large-scale deployment of CARBIOS’ PET biorecycling technology in Asia, with the first step being the construction of a PET biorecycling plant in China.




CARBIOS and Wankai New Materials, a subsidiary of Zhink Group, are committed to the large-scale deployment of CARBIOS’ PET biorecycling technology in Asia, with the first step being the construction of a PET biorecycling plant in China.

• The two Groups have reached a binding agreement on the main principles of their collaboration, with a view to deploying a capacity of one million tonnes in the long term,
• Starting with the construction of a plant in China with a processing capacity of 50,000 tonnes of PET waste per year.
• This collaboration remains subject to the signing of final agreements.

Clermont-Ferrand (France), November 6, 2025 (08:30am CET). Following the Letter of intent signed on June 24, 2024, CARBIOS (Euronext Growth Paris: ALCRB) and Wankai New Materials (“Wankai”), a listed¹ subsidiary of Zhink Group, 3^rd largest PET producer in China and 4^th globally, announce the signing of an agreement on the fundamental principles of a collaboration aiming to deploy CARBIOS PET enzymatic recycling technology in Asia.

Under the terms of this agreement, CARBIOS and Wankai would enter into a long-term commitment with the ambition to build and operate several PET biorecycling plants in Asia with a target capacity of one million tonnes per year. CARBIOS would grant, to the joint ventures formed under this agreement, an exclusive licence of CARBIOS technology for the Asian region.

The first step of this collaboration will be the creation of a joint venture dedicated to the construction and operation of a first PET biorecycling plant in China, with an annual processing capacity of 50,000 tonnes of PET waste per year. CARBIOS will grant to this entity a licence to produce PTA and MEG monomers.

The financing of this future joint venture, in which Wankai would be the main shareholder, will be guaranteed by the latter. The construction project for the first plant is expected to start in the first quarter of 2026.

In addition, Wankai would make a € 5 million investment in CARBIOS S.A.². This investment would strengthen the strategic partnership between the two companies.

This project of partnership, including the project of a first plant and investment in CARBIOS, remains subject to the finalization and signature of the definitive agreements, in particular the shareholders’ agreement and the licence agreement. The parties’ objective is to have them signed by the end of 2025.

This agreement would mark the first licence for CARBIOS’ technology whereby confirming the viability of its business model.

As the world leading producer of PET, China is a key market for CARBIOS. This agreement represents a strategic step forward for both partners, who are determined to accelerate the development of a circular PET industry in Asia.

Vincent Kamel, CEO of CARBIOS: “This agreement represents a key step in the international roll-out of our technology and an important milestone in the implementation of our licensing model. This cooperation with Wankai, China’s third-largest PET producer, will enable us to produce enzymatically recycled PET and thus make a concrete contribution to the transition to a more circular and low-carbon PET industry.”

###

About CARBIOS:
CARBIOS is a biotechnology company that develops and industrializes biological solutions to reinvent the lifecycle of plastics and textiles. Inspired by nature, CARBIOS designs enzyme-based biological processes to break down plastics, with the mission of preventing plastic and textile pollution and accelerating the transition to a circular economy. Its two innovative technologies—dedicated to PET biorecycling and PLA biodegradation—are currently scaling up to industrial and commercial levels. Its industrial demonstration plant for biorecycling has been operational since 2021, and construction of the world’s first biorecycling plant is expected to resume before the end of 2025, subject to securing the necessary additional funding. CARBIOS is supported by prestigious brands in the cosmetics, food, and apparel industries, aiming to improve the recyclability and circularity of their products. Nestlé Waters, PepsiCo, and Suntory Beverage & Food Europe are members of a packaging consortium founded by CARBIOS and L’Oréal. On, Patagonia, PUMA, PVH Corp., and Salomon collaborate with CARBIOS in a textile consortium. CARBIOS is part of the global community of B Corp™ certified companies that are transforming their business models to serve the common good.

Visit www.carbios.com to learn more about biotechnology for circular plastics and textiles.

LinkedIn : carbios / Instagram : carbios

Information on CARBIOS shares:

ISIN Code: FR0011648716
Ticker Code: Euronext Growth: ALCRB
LEI: 969500M2RCIWO4NO5F08

CARBIOS is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.

Disclaimer on forward-looking statements and risk factors:
This press release contains forward-looking statements, not historical data, and should not be construed as a guarantee that the facts and data stated will occur. These forward-looking statements are based on data, assumptions and estimates considered reasonable by CARBIOS. CARBIOS operates in a competitive and rapidly evolving environment. It is therefore not in a position to anticipate all risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of a risk or combination of risks could lead to results that differ significantly from those mentioned in any forward-looking statement. CARBIOS draws your attention to the fact that forward-looking statements are in no way a guarantee of its future performance and that its actual financial position, results, cash flows, its partnerships and corporate agreements, and the development of the sector in which CARBIOS operates may differ significantly from those proposed or suggested by the forward-looking statements contained in this document. In addition, even if CARBIOS’ financial position, results, cash flows, its partnerships and corporate agreements, and developments in the industry in which it operates are consistent with the forward-looking information contained in this document, such results or developments may not be a reliable indication of CARBIOS’ future results or developments. Readers are also advised to carefully consider the risk factors described in the Universal registration document filed with the French Market Authority (“AMF”), as well as in the half-year financial report available free of charge on the Company’s website. Should all or any part of these risk factors occur or others, in no case whatsoever will CARBIOS be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages. This information is given only as of the date of this press release. CARBIOS makes no commitment to publish updates to this information or on the assumptions on which it is based, except in accordance with any legal or regulatory obligation applicable to it.

For additional information, please contact:

1 Wankai New Materials is a company listed on the Shenzhen Stock Exchange (stock code:301216)

² As a result of this investment, Wankai could appoint a representative to CARBIOS’ Board of Directors. The terms and conditions of the capital investment, particularly the financial terms, are still to be finalized in the definitive agreements. This investment will, if necessary, be subject to administrative and regulatory approvals in France and Chine.

Attachment

• 2025 11 06 PR CARBIOS x WANKAI

8% organic sales growth after first nine months. Full-year organic sales growth narrowed upwards.




8% organic sales growth after first nine months. Full-year organic sales growth narrowed upwards.

Ester Baiget, President & CEO: ”I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability and cash flow. Our performance was strong across all sales areas and in Emerging and Developed Markets. We delivered 37.3% adjusted EBITDA margin, despite significant currency headwinds, demonstrating the strength and resilience of our business model. Following a robust nine-months performance including favorable timing in the third quarter, we indicate mid-single-digit organic sales growth for the fourth quarter and lift the bottom end of the range now expecting 7-8% for the full year. We continue to successfully execute on our strategic priorities, positioning us firmly to deliver on our 2030 targets.”

• Strong broad-based organic sales growth of 8% (Q3: 6%), including the negative impact of exiting certain countries of ~1 percentage point (Q3: ~2 percentage points). Price contributed by ~1 percentage point (Q3: ~1 percentage point).
• Food & Health at 9% organic sales growth (Q3: 6%) including the negative impact of exiting certain countries of ~2 percentage points (Q3: ~5 percentage points). Planetary Health at 8% organic sales growth (Q3: 6%).
• Emerging Markets at 12% organic sales growth (Q3: 10%); Developed Markets at 6% organic sales growth (Q3: 4%).
• Adjusted EBITDA margin at 37.3% (Q3: 37.1%), up by 130 bps (Q3: down by 30 bps). including significant currency headwinds. Adjusted net profit increased by 22% (Q3: 19%).
• NIBD/EBITDA at 2.0x, and free cash flow before acquisitions at EUR 668.4 million (Q3: EUR 361.3 million).
• 2025 outlook: Organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in Q4 following favorable timing in Q3. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%). The adjusted EBITDA margin is expected at the lower end of the 37-38% range, including significant currency headwinds.

Please read the full announcement in PDF.

Attachment

• 2025_46_9M_Interim report

8% organic sales growth after first nine months. Full-year organic sales growth narrowed upwards.




8% organic sales growth after first nine months. Full-year organic sales growth narrowed upwards.

Ester Baiget, President & CEO: ”I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability and cash flow. Our performance was strong across all sales areas and in Emerging and Developed Markets. We delivered 37.3% adjusted EBITDA margin, despite significant currency headwinds, demonstrating the strength and resilience of our business model. Following a robust nine-months performance including favorable timing in the third quarter, we indicate mid-single-digit organic sales growth for the fourth quarter and lift the bottom end of the range now expecting 7-8% for the full year. We continue to successfully execute on our strategic priorities, positioning us firmly to deliver on our 2030 targets.”

• Strong broad-based organic sales growth of 8% (Q3: 6%), including the negative impact of exiting certain countries of ~1 percentage point (Q3: ~2 percentage points). Price contributed by ~1 percentage point (Q3: ~1 percentage point).
• Food & Health at 9% organic sales growth (Q3: 6%) including the negative impact of exiting certain countries of ~2 percentage points (Q3: ~5 percentage points). Planetary Health at 8% organic sales growth (Q3: 6%).
• Emerging Markets at 12% organic sales growth (Q3: 10%); Developed Markets at 6% organic sales growth (Q3: 4%).
• Adjusted EBITDA margin at 37.3% (Q3: 37.1%), up by 130 bps (Q3: down by 30 bps). including significant currency headwinds. Adjusted net profit increased by 22% (Q3: 19%).
• NIBD/EBITDA at 2.0x, and free cash flow before acquisitions at EUR 668.4 million (Q3: EUR 361.3 million).
• 2025 outlook: Organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in Q4 following favorable timing in Q3. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%). The adjusted EBITDA margin is expected at the lower end of the 37-38% range, including significant currency headwinds.

Please read the full announcement in PDF.

Attachment

• 2025_46_9M_Interim report

Interim Report Q3 2025: Solid quarter with 1% organic growth, 11% EBITA margin and DKK 410 million cash flow




Interim Report Q3 2025: Solid quarter with 1% organic growth, 11% EBITA margin and DKK 410 million cash flow

Highlights

• The Hearing division delivered 7% organic revenue growth driven by the continued strong performance of ReSound Vivia, enabling broad-based market share gains. The divisional profit margin ended at 34%, driven by positive operating leverage, but partly offset by negative country mix
• The Enterprise division continued to experience positive sell-out growth outside of Europe, driven by strong channel execution and market leading innovation, while Europe continued to be challenged due to market uncertainty. Reflecting continued inventory reductions in North America, organic revenue growth ended at -4%. The divisional profit margin ended at 34%, as a result of negative operating leverage and tariff headwinds offset by price increases and cost focus
• The Gaming division continued to perform well and take share in a challenged market, delivering organic growth of 3%. The divisional profit margin (excluding wind-down effects) ended at 9%, reflecting tariff costs, partly offset by price increases
• Group reported EBITA ended at DKK 435 million (equal to an EBITA margin of 11%), reflecting the development in revenue and the strong cost focus
• Free cash flow excl. M&A ended at DKK 410 million reflecting the earnings profile and positive impact on working capital. Net interest-bearing debt ended at DKK 9.4 billion, equaling a reported leverage of 4.0x (reported leverage of 4.3x in Q3 2024)
• Following a successful execution in the first nine months of the year, GN’s financial guidance for 2025 is confirmed

Financial guidance for 2025

Key revenue assumptions for the financial guidance 2025

Hearing division
GN is exposed to an attractive hearing aid market, which has historically been growing 4-6% in volumes driven by ongoing favorable demographic trends. With an assumed -1% yearly ASP impact, the structural market value growth assumptions of 3-5%. As a consequence of the slower beginning of the year driven by the uncertain macroeconomic environment, it is still expected that the market in 2025 will grow slower than its structural trend. Based on the strong sales momentum of ReSound Vivia and ReSound Savi, GN in 2025 expects to continue to gain market share. In the beginning of 2025, we assumed the Hearing division to contribute with organic revenue growth of 5% to 9%. Due to the lower market growth assumption, it is still assumed that the Hearing division will grow at the lower half of that range.

Enterprise division
The uncertainty and change in the trade environment are impacting our Enterprise division. We have taken significant actions to further diversify our manufacturing footprint to mitigate this, and we have also implemented targeted price adjustments in the U.S. With these initiatives in place, we are progressing well towards the existing assumptions for the year. In April 2025, we assumed the Enterprise division would contribute with organic revenue growth of -8% to 0%, and we are continuing to assume a contribution in the middle of this range.

Gaming division
Similar to the Enterprise market, the Gaming market is also impacted by the change in trade environment and general weak consumer sentiment. We have taken several mitigation actions including diversification of our manufacturing footprint and targeted price increases. These initiatives work well. In April 2025, we assumed the Gaming division to contribute with organic revenue growth of -6% to +2% (excluding the impact from the wind-down). Driven by the strong execution in the first nine months of the year, the Gaming division is still assuming to contribute with organic revenue growth in the upper half of that range.

Key EBITA margin assumptions for the financial guidance of 2025
In light of the evolving changes in the global trade environment, GN launched significant mitigation actions in May 2025 to protect Group profitability. These significant actions included but were not limited to 1) Acceleration of diversification of manufacturing footprint; 2) U.S. price increases for Enterprise and Gaming; 3) Group-wide cost and cash initiatives.

In the quarter, the changing trade environment has been managed well. The efforts to diversify the supply chain are now more or less concluded, meaning that GN will be able to serve the vast majority of the U.S. market with manufacturing outside of China by the end of 2025. Thanks to this, the group-wide cost control efforts and the commercial actions that were taken across Enterprise and Gaming, the overall impact is being mitigated well. We are continuously assessing the developments and additional prudent and diligent actions will be taken as needed going forward. It is still expected that the net impact from tariffs will impact group EBITA margin by around -1% in 2025 (as earlier communicated), of which around 0.5% has a more temporary effect.

Quotes from Executive Management
Peter Karlstromer, CEO of GN Store Nord, comments: “We are executing well across our priorities in markets currently growing below normal trends. The diversification of our manufacturing footprint progresses according to plan, and this together with commercial levers and cost control help us manage the tariff situation in line with our plans. We continue to see the benefits of our market-leading product portfolio, and remain excited about our innovation pipeline to support GN’s growth in the years to come.“

Financial overview Q3 2025

* Excluding wind-down effect. Reported organic revenue growth of -1%

Teleconference
GN Store Nord will host a teleconference at 11.00 a.m. CET on November 6, 2025. Please visit www.gn.com/investor to access the teleconference. Presentation material will be available on the website prior to the start of the teleconference.

For further information, please contact:

Investor Relations
Rune Sandager +45 45 75 92 57

Media Relations
Steen Frentz Laursen +45 20 65 34 20

Forward-looking statements
The forward-looking statements in this report reflect the management’s current expectations of certain future events and financial results. Statements regarding the future are, naturally, subject to risks and uncertainties, which may result in considerable deviations from the outlook set forth. Furthermore, some of these expectations are based on assumptions regarding future events, which may prove incorrect. Changes to such expectations and assumptions will not be disclosed on an ongoing basis, unless required pursuant to general disclosure obligations to which GN is subject.

Factors that may cause actual results to deviate materially from expectations include – but are not limited to – general economic developments and developments in the financial markets as well as foreign exchange rates, technological developments, changes and amendments to legislation and regulations governing GN’s markets, changes in the demand for GN’s products, competition, fluctuations in sub-contractor supplies, and developments in ongoing litigation (including but not limited to class action and patent infringement litigation in the United States).

For more information, please see the “Management’s report” and “Risk management” sections in the Annual Report. This Report should not be considered an offer to sell securities in GN.

About GN
GN brings people closer through our leading intelligent hearing, audio, video, and gaming solutions. Inspired by people and driven by innovation, we deliver technologies that enhance the senses of hearing and sight. We help people with hearing loss overcome real-life challenges, improve communication and collaboration for businesses, and provide great experiences for audio and gaming enthusiasts. GN was founded more than 150 years ago with a vision to connect the world. Today, inspired by our strong heritage, GN touches more lives than ever with our unique expertise and the broadest portfolio of products and services in our history – bringing people closer to what is important to them.

We market our solutions with the brands Jabra, ReSound, SteelSeries, Beltone, Interton, BlueParrott, Danavox, and FalCom in 100 countries. Founded in 1869, GN Group employs more than 7,000 people and is listed on Nasdaq Copenhagen (GN.CO).

Visit our homepage GN.com and connect with us on LinkedIn, Facebook and X.

Attachment

• GN Interim Report Q3 2025

Interim Report Q3 2025: Solid quarter with 1% organic growth, 11% EBITA margin and DKK 410 million cash flow




Interim Report Q3 2025: Solid quarter with 1% organic growth, 11% EBITA margin and DKK 410 million cash flow

Highlights

• The Hearing division delivered 7% organic revenue growth driven by the continued strong performance of ReSound Vivia, enabling broad-based market share gains. The divisional profit margin ended at 34%, driven by positive operating leverage, but partly offset by negative country mix
• The Enterprise division continued to experience positive sell-out growth outside of Europe, driven by strong channel execution and market leading innovation, while Europe continued to be challenged due to market uncertainty. Reflecting continued inventory reductions in North America, organic revenue growth ended at -4%. The divisional profit margin ended at 34%, as a result of negative operating leverage and tariff headwinds offset by price increases and cost focus
• The Gaming division continued to perform well and take share in a challenged market, delivering organic growth of 3%. The divisional profit margin (excluding wind-down effects) ended at 9%, reflecting tariff costs, partly offset by price increases
• Group reported EBITA ended at DKK 435 million (equal to an EBITA margin of 11%), reflecting the development in revenue and the strong cost focus
• Free cash flow excl. M&A ended at DKK 410 million reflecting the earnings profile and positive impact on working capital. Net interest-bearing debt ended at DKK 9.4 billion, equaling a reported leverage of 4.0x (reported leverage of 4.3x in Q3 2024)
• Following a successful execution in the first nine months of the year, GN’s financial guidance for 2025 is confirmed

Financial guidance for 2025

Key revenue assumptions for the financial guidance 2025

Hearing division
GN is exposed to an attractive hearing aid market, which has historically been growing 4-6% in volumes driven by ongoing favorable demographic trends. With an assumed -1% yearly ASP impact, the structural market value growth assumptions of 3-5%. As a consequence of the slower beginning of the year driven by the uncertain macroeconomic environment, it is still expected that the market in 2025 will grow slower than its structural trend. Based on the strong sales momentum of ReSound Vivia and ReSound Savi, GN in 2025 expects to continue to gain market share. In the beginning of 2025, we assumed the Hearing division to contribute with organic revenue growth of 5% to 9%. Due to the lower market growth assumption, it is still assumed that the Hearing division will grow at the lower half of that range.

Enterprise division
The uncertainty and change in the trade environment are impacting our Enterprise division. We have taken significant actions to further diversify our manufacturing footprint to mitigate this, and we have also implemented targeted price adjustments in the U.S. With these initiatives in place, we are progressing well towards the existing assumptions for the year. In April 2025, we assumed the Enterprise division would contribute with organic revenue growth of -8% to 0%, and we are continuing to assume a contribution in the middle of this range.

Gaming division
Similar to the Enterprise market, the Gaming market is also impacted by the change in trade environment and general weak consumer sentiment. We have taken several mitigation actions including diversification of our manufacturing footprint and targeted price increases. These initiatives work well. In April 2025, we assumed the Gaming division to contribute with organic revenue growth of -6% to +2% (excluding the impact from the wind-down). Driven by the strong execution in the first nine months of the year, the Gaming division is still assuming to contribute with organic revenue growth in the upper half of that range.

Key EBITA margin assumptions for the financial guidance of 2025
In light of the evolving changes in the global trade environment, GN launched significant mitigation actions in May 2025 to protect Group profitability. These significant actions included but were not limited to 1) Acceleration of diversification of manufacturing footprint; 2) U.S. price increases for Enterprise and Gaming; 3) Group-wide cost and cash initiatives.

In the quarter, the changing trade environment has been managed well. The efforts to diversify the supply chain are now more or less concluded, meaning that GN will be able to serve the vast majority of the U.S. market with manufacturing outside of China by the end of 2025. Thanks to this, the group-wide cost control efforts and the commercial actions that were taken across Enterprise and Gaming, the overall impact is being mitigated well. We are continuously assessing the developments and additional prudent and diligent actions will be taken as needed going forward. It is still expected that the net impact from tariffs will impact group EBITA margin by around -1% in 2025 (as earlier communicated), of which around 0.5% has a more temporary effect.

Quotes from Executive Management
Peter Karlstromer, CEO of GN Store Nord, comments: “We are executing well across our priorities in markets currently growing below normal trends. The diversification of our manufacturing footprint progresses according to plan, and this together with commercial levers and cost control help us manage the tariff situation in line with our plans. We continue to see the benefits of our market-leading product portfolio, and remain excited about our innovation pipeline to support GN’s growth in the years to come.“

Financial overview Q3 2025

* Excluding wind-down effect. Reported organic revenue growth of -1%

Teleconference
GN Store Nord will host a teleconference at 11.00 a.m. CET on November 6, 2025. Please visit www.gn.com/investor to access the teleconference. Presentation material will be available on the website prior to the start of the teleconference.

For further information, please contact:

Investor Relations
Rune Sandager +45 45 75 92 57

Media Relations
Steen Frentz Laursen +45 20 65 34 20

Forward-looking statements
The forward-looking statements in this report reflect the management’s current expectations of certain future events and financial results. Statements regarding the future are, naturally, subject to risks and uncertainties, which may result in considerable deviations from the outlook set forth. Furthermore, some of these expectations are based on assumptions regarding future events, which may prove incorrect. Changes to such expectations and assumptions will not be disclosed on an ongoing basis, unless required pursuant to general disclosure obligations to which GN is subject.

Factors that may cause actual results to deviate materially from expectations include – but are not limited to – general economic developments and developments in the financial markets as well as foreign exchange rates, technological developments, changes and amendments to legislation and regulations governing GN’s markets, changes in the demand for GN’s products, competition, fluctuations in sub-contractor supplies, and developments in ongoing litigation (including but not limited to class action and patent infringement litigation in the United States).

For more information, please see the “Management’s report” and “Risk management” sections in the Annual Report. This Report should not be considered an offer to sell securities in GN.

About GN
GN brings people closer through our leading intelligent hearing, audio, video, and gaming solutions. Inspired by people and driven by innovation, we deliver technologies that enhance the senses of hearing and sight. We help people with hearing loss overcome real-life challenges, improve communication and collaboration for businesses, and provide great experiences for audio and gaming enthusiasts. GN was founded more than 150 years ago with a vision to connect the world. Today, inspired by our strong heritage, GN touches more lives than ever with our unique expertise and the broadest portfolio of products and services in our history – bringing people closer to what is important to them.

We market our solutions with the brands Jabra, ReSound, SteelSeries, Beltone, Interton, BlueParrott, Danavox, and FalCom in 100 countries. Founded in 1869, GN Group employs more than 7,000 people and is listed on Nasdaq Copenhagen (GN.CO).

Visit our homepage GN.com and connect with us on LinkedIn, Facebook and X.

Attachment

• GN Interim Report Q3 2025